Canaccord has increased its price target for ASP Isotopes (ASPI, Financial) from $8.50 to $11, maintaining a Buy rating on the company's stock. This optimistic adjustment is attributed to the company's promising agreements with TerraPower. These agreements involve financial backing for the development of a new uranium enrichment facility. This facility is designed to produce High Assay Low-Enriched Uranium (HALEU) and supply it to TerraPower. Canaccord sees potential for further gains from this transaction and is confident in management's capabilities to deliver on these commitments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for ASP Isotopes Inc (ASPI, Financial) is $6.50 with a high estimate of $8.50 and a low estimate of $4.50. The average target implies an downside of 7.14% from the current price of $7.00. More detailed estimate data can be found on the ASP Isotopes Inc (ASPI) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, ASP Isotopes Inc's (ASPI, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
